Seattle Genetics Company Profile (NASDAQ:SGEN)

About Seattle Genetics

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SGEN
  • CUSIP: 81257810
Key Metrics:
  • Previous Close: $62.73
  • 50 Day Moving Average: $60.50
  • 200 Day Moving Average: $57.18
  • 52-Week Range: $142,493,000.00 - $29.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -57.03
  • P/E Growth: -1.93
  • Market Cap: $8.94B
  • Outstanding Shares: 142,493,000
  • Beta: 2.25
Profitability:
  • Net Margins: -33.51%
  • Return on Equity: -20.86%
  • Return on Assets: -16.21%
Debt:
  • Current Ratio: 5.92%
  • Quick Ratio: 5.35%
Additional Links:
Companies Related to Seattle Genetics:

Analyst Ratings

Consensus Ratings for Seattle Genetics (NASDAQ:SGEN) (?)
Ratings Breakdown: 3 Sell Ratings, 7 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.13)
Consensus Price Target: $58.85 (6.19% downside)

Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)
Show:
DateFirmActionRatingPrice TargetDetails
2/16/2017Bank of America CorpDowngradeNeutral -> UnderperformView Rating Details
2/13/2017Credit Suisse GroupBoost Price TargetNeutral$62.00 -> $66.00View Rating Details
2/10/2017HC WainwrightReiterated RatingBuy$65.00View Rating Details
1/5/2017RBC Capital MarketsSet Price TargetBuy$80.00View Rating Details
1/5/2017Maxim GroupReiterated RatingReduceView Rating Details
12/28/2016Cantor FitzgeraldReiterated RatingNeutral$43.00View Rating Details
12/27/2016Needham & Company LLCReiterated RatingHold$72.00View Rating Details
12/12/2016Cowen and CompanyReiterated RatingHold$47.00View Rating Details
12/6/2016Royal Bank of CanadaBoost Price TargetOutperform$62.00 -> $72.00View Rating Details
11/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$53.00 -> $70.00View Rating Details
10/31/2016J P Morgan Chase & CoReiterated RatingHold$43.00View Rating Details
10/24/2016Leerink SwannReiterated RatingOutperform$62.00View Rating Details
9/16/2016Goldman Sachs Group, Inc. (The)DowngradeNeutral -> SellView Rating Details
9/7/2016Morgan StanleyInitiated CoverageOverweight$60.00View Rating Details
7/27/2016SunTrust Banks, Inc.Boost Price TargetNeutral$34.00 -> $38.00View Rating Details
2/11/2016Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformView Rating Details
2/10/2016Piper Jaffray CompaniesLower Price TargetNeutral$44.00 -> $33.00View Rating Details
8/25/2015William BlairReiterated RatingBuyView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Seattle Genetics (NASDAQ:SGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017        
2/9/2017Q416($0.34)($0.39)$106.49 million$105.30 millionViewListenView Earnings Details
10/27/2016Q316($0.29)($0.23)$4.34 million$106.30 millionViewListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)
Current Year EPS Consensus Estimate: $-1.88 EPS
Next Year EPS Consensus Estimate: $-1.10 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20161($0.29)($0.29)($0.29)
Q3 20161($0.35)($0.35)($0.35)
Q4 20161($0.36)($0.36)($0.36)
Q2 20171($0.28)($0.28)($0.28)
Q3 20171($0.26)($0.26)($0.26)
Q4 20171($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Seattle Genetics (NASDAQ:SGEN)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 98.43%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/6/2017Clay B SiegallInsiderSell14,465$61.54$890,176.10View SEC Filing  
1/6/2017Clay B. SiegallInsiderSell14,465$57.89$837,378.85View SEC Filing  
12/13/2016Darren S. ClineEVPSell10,000$63.38$633,800.00View SEC Filing  
12/8/2016Eric DobmeierCOOSell12,500$65.92$824,000.00View SEC Filing  
12/7/2016Vaughn B. HimesInsiderSell30,000$65.32$1,959,600.00View SEC Filing  
11/8/2016Felix BakerDirectorBuy382,500$59.36$22,705,200.00View SEC Filing  
11/7/2016Clay B. SiegallCEOSell14,465$58.43$845,189.95View SEC Filing  
11/7/2016Marc E. LippmanDirectorSell1,000$57.75$57,750.00View SEC Filing  
11/3/2016Felix BakerDirectorBuy1,030,629$56.13$57,849,205.77View SEC Filing  
11/1/2016Jonathan G. DrachmanCMOSell3,418$51.74$176,847.32View SEC Filing  
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.62View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.25View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.44View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.57View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.36View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.00View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.92View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.00View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.00View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.62View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.96View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.24View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.94View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.77View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.20View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.75View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.48View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.19View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.23View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.76View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Seattle Genetics (NASDAQ:SGEN)
DateHeadline
finance.yahoo.com logoImmunomedics Issues Open Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation (NASDAQ:SGEN)
finance.yahoo.com - February 27 at 9:18 AM
finance.yahoo.com logoSEATTLE GENETICS INC /WA Financials (NASDAQ:SGEN)
finance.yahoo.com - February 25 at 7:22 PM
4-traders.com logoSeattle Genetics, Inc. : Pawar Law Group Announces that a Securities Class Action Lawsuit has been filed Against Seattle Genetics, Inc. - SGEN (NASDAQ:SGEN)
www.4-traders.com - February 24 at 9:49 PM
finance.yahoo.com logoBear of the Day: Seattle Genetics (SGEN) (NASDAQ:SGEN)
finance.yahoo.com - February 24 at 9:49 PM
finance.yahoo.com logoINVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:SGEN)
finance.yahoo.com - February 24 at 9:49 PM
finance.yahoo.com logoPawar Law Group Announces that a Securities Class Action Lawsuit has been filed Against Seattle Genetics, Inc. - SGEN (NASDAQ:SGEN)
finance.yahoo.com - February 24 at 6:28 AM
investopedia.com logoImmunomedics Sues Board Over Seattle Genetics Deal (NASDAQ:SGEN)
www.investopedia.com - February 23 at 7:57 PM
nasdaq.com logoFirst Week of April 21st Options Trading For Seattle Genetics (NASDAQ:SGEN)
www.nasdaq.com - February 23 at 12:59 AM
News IconTrading Roundup: Checking Technicals for Seattle Genetics Inc (SGEN) - Baxter Review (NASDAQ:SGEN)
baxternewsreview.com - February 22 at 7:58 PM
prnewswire.com logoSGEN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action ... - PR Newswire (press release) (NASDAQ:SGEN)
www.prnewswire.com - February 22 at 7:58 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017 (NASDAQ:SGEN)
finance.yahoo.com - February 22 at 7:58 PM
finance.yahoo.com logoSGEN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017 (NASDAQ:SGEN)
finance.yahoo.com - February 22 at 7:58 PM
finance.yahoo.com logoSGEN SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:SGEN)
finance.yahoo.com - February 22 at 7:58 PM
News IconCompany Scope: Tracking Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) - Baldwin Journal (NASDAQ:SGEN)
baldwinjournal.com - February 22 at 9:49 AM
biz.yahoo.com logoSEATTLE GENETICS INC /WA Files SEC form 10-K, Annual Report (NASDAQ:SGEN)
biz.yahoo.com - February 22 at 9:49 AM
News IconEPS Of Seattle Genetics, Inc. (NASDAQ:SGEN) At $-0.42 - Stock Observer (NASDAQ:SGEN)
www.thestockobserver.com - February 18 at 6:49 PM
marketexclusive.com logoSeattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:SGEN)
marketexclusive.com - February 17 at 7:39 PM
News IconNASDAQ:SGEN Shareholder News: Lawsuit alleges Misleading Statements by Seattle Genetics, Inc. (NASDAQ:SGEN)
www.groundreport.com - February 17 at 7:39 PM
us.rd.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN (NASDAQ:SGEN)
us.rd.yahoo.com - February 17 at 7:39 PM
us.rd.yahoo.com logoSHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:SGEN)
us.rd.yahoo.com - February 17 at 7:39 PM
4-traders.com logoSEATTLE GENETICS INC /WA : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:SGEN)
www.4-traders.com - February 16 at 7:30 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017 (NASDAQ:SGEN)
finance.yahoo.com - February 16 at 7:29 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:SGEN)
finance.yahoo.com - February 16 at 7:29 PM
finance.yahoo.com logoSGEN NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors of Important Deadline in Class Action – SGEN (NASDAQ:SGEN)
finance.yahoo.com - February 16 at 7:29 PM
finance.yahoo.com logoSGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:SGEN)
finance.yahoo.com - February 16 at 7:29 PM
biz.yahoo.com logoSEATTLE GENETICS INC /WA Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat (NASDAQ:SGEN)
biz.yahoo.com - February 16 at 7:29 PM
openpr.com logoSeattle Genetics, Inc. (NASDAQ:SGEN) Investor Lawsuit alleges False and Misleading Statements (NASDAQ:SGEN)
www.openpr.com - February 15 at 5:01 AM
capitalcube.com logoSeattle Genetics, Inc. :SGEN-US: Earnings Analysis: 2016 By the Numbers : February 14, 2017 (NASDAQ:SGEN)
us.rd.yahoo.com - February 15 at 5:01 AM
us.rd.yahoo.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm (NASDAQ:SGEN)
us.rd.yahoo.com - February 15 at 5:01 AM
News IconSeattle Genetics, Inc. (SGEN) Downgraded by Bank of America Corporation to "Underperform" (NASDAQ:SGEN)
ekosvoice.com - February 14 at 6:18 AM
News IconThe Seattle Genetics, Inc. (SGEN) Issues Earnings Results (NASDAQ:SGEN)
eleganthomesinla.com - February 14 at 6:18 AM
News IconWhat directions Seattle Genetics, Inc. (NASDAQ:SGEN) insiders are heading (NASDAQ:SGEN)
nyhetsbanken.info - February 14 at 6:18 AM
News IconSeattle Genetics, Inc. (SGEN) Shares Gap Down After Earnings Miss (NASDAQ:SGEN)
hoyentv.com - February 14 at 6:18 AM
capitalcube.com logoSeattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 13, 2017 (NASDAQ:SGEN)
us.rd.yahoo.com - February 14 at 6:18 AM
us.rd.yahoo.com logoSGEN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017 (NASDAQ:SGEN)
us.rd.yahoo.com - February 14 at 6:18 AM
News IconImmunomedics, Inc. (NASDAQ:IMMU) And Seattle Genetics, Inc. Deal Comes With An Open End (NASDAQ:SGEN)
www.financialstrend.com - February 13 at 8:25 AM
4-traders.com logoSeattle Genetics : to Present at Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:SGEN)
www.4-traders.com - February 13 at 8:25 AM
finance.yahoo.com logoSeattle Genetics to Present at Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:SGEN)
finance.yahoo.com - February 13 at 8:25 AM
finance.yahoo.com logoBlog Coverage Immunomedics Announces a $2 Billion Cancer Deal with Seattle Genetics (NASDAQ:SGEN)
finance.yahoo.com - February 13 at 8:25 AM
fool.com logoWill Seattle Genetics' Deal With Immunomedics Get Scuttled? (NASDAQ:SGEN)
www.fool.com - February 12 at 3:30 PM
News IconSeattle Genetics, Inc. (NASDAQ:SGEN) Quarterly EPS Projection At $-0.3 - Stock Observer (NASDAQ:SGEN)
www.thestockobserver.com - February 12 at 12:53 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle ... - Yahoo Finance (NASDAQ:SGEN)
finance.yahoo.com - February 12 at 12:53 AM
seekingalpha.com logoSeattle Genetics (SGEN) Q4 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:SGEN)
seekingalpha.com - February 12 at 12:53 AM
bizjournals.com logoSeattle Genetics CEO charts path to becoming Washington's biggest biotech ever (NASDAQ:SGEN)
www.bizjournals.com - February 11 at 1:45 AM
streetinsider.com logoSeattle Genetics (SGEN) and Immunomedics (IMMU) Sign Global License Agreement for Sacituzumab Govitecan (IMMU-132) (NASDAQ:SGEN)
www.streetinsider.com - February 11 at 1:45 AM
News IconSeattle Genetics pays $250 million for drug rights (NASDAQ:SGEN)
mundoaguaysaneamiento.net - February 11 at 1:45 AM
News IconSeattle Genetics, Inc. (SGEN) Releases Earnings Results, Misses Estimates By $0.05 EPS (NASDAQ:SGEN)
techknowbits.com - February 11 at 1:45 AM
us.rd.yahoo.com logoSeattle Genetics 4Q Loss 39 Cents/Share Misses Street (NASDAQ:SGEN)
us.rd.yahoo.com - February 11 at 1:45 AM
prnewswire.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages ... - PR Newswire (press release) (NASDAQ:SGEN)
www.prnewswire.com - February 10 at 3:14 AM
News IconNews Impact Score Of Seattle Genetics, Inc. (NASDAQ:SGEN) At 41 - Stock Observer (NASDAQ:SGEN)
www.thestockobserver.com - February 10 at 3:14 AM

Social

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

Where is Seattle Genetics' stock going? Where will Seattle Genetics' stock price be in 2017?

15 brokerages have issued 1-year price objectives for Seattle Genetics' stock. Their predictions range from $38.00 to $80.00. On average, they anticipate Seattle Genetics' stock price to reach $58.85 in the next year.

When will Seattle Genetics announce their earnings?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:

  • HC Wainwright analysts commented, "CVT-301 data may be good start to 2017. ACOR released top-line data from the pivotal study of CVT-301 (pulmonary inhaled levodopa) this morning. The company reported that the 80mg dose (but not the 60mg dose) produced a statistically significant (p=0.009) improvement in the Unified Parkinson’s Diseases Rating Scale Part-3 (UPDRS III) with a placebo-adjusted treatment effect of -3.92 (-9.83 score for CVT-301)." (2/10/2017)

  • According to Zacks Investment Research, "Seattle Genetics’ sole dependence on a single product – Adcetris – for growth has its inherent risks. A decline in Adcetris sales will hurt the company's top line. The company has a number of candidates in its pipeline, most of which are in the early stages of development. Any hiccup in their development would adversely affect the stock. Moreover, potential competition in the near future put up tough challenges for the company's revenues. Loss estimates are stable ahead its Q4 release. However, the company’s collaboration agreement with Takeda for the global development and commercialization of Adcetris is encouraging. Also, collaborations with companies like AbbVie, Bayer, Roche and Pfizer provide it with funds in the form of upfront, milestone and other payments. The company’s shares have outperformed the Medical-Biomedical/Genetics industry in the past one year." (1/17/2017)

  • Cowen and Company analysts commented, "SGEN presented updated Phase I data for SGN-LIV1A in mBC this weekend at SABCS." (12/12/2016)

Who owns Seattle Genetics stock?

Seattle Genetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.68%), FMR LLC (8.32%), State Street Corp (1.81%), Artisan Partners Limited Partnership (1.54%), Pinnacle Associates Ltd. (0.78%) and Columbia Wanger Asset Management LLC (0.54%). Company insiders that own Seattle Genetics stock include Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Felix Baker, John A Orwin, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes.

Who sold Seattle Genetics stock? Who is selling Seattle Genetics stock?

Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, FMR LLC, Eventide Asset Management LLC, Baillie Gifford & Co., Boxer Capital LLC, Pinnacle Associates Ltd., Allianz Asset Management AG and Guggenheim Capital LLC. Company insiders that have sold Seattle Genetics stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman and Vaughn B Himes.

Who bought Seattle Genetics stock? Who is buying Seattle Genetics stock?

Seattle Genetics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Two Sigma Investments LP, Renaissance Technologies LLC, Russell Investments Group Ltd., Asset Management One Co. Ltd., Columbia Wanger Asset Management LLC, Janus Capital Management LLC and AQR Capital Management LLC. Company insiders that have bought Seattle Genetics stock in the last two years include Felix Baker and John A Orwin.

How do I buy Seattle Genetics stock?

Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Seattle Genetics stock cost?

One share of Seattle Genetics stock can currently be purchased for approximately $62.73.

Seattle Genetics (NASDAQ:SGEN) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Earnings History Chart

Earnings by Quarter for Seattle Genetics (NASDAQ:SGEN)

Dividend History Chart

Dividend Payments by Quarter for Seattle Genetics (NASDAQ:SGEN)

Last Updated on 2/27/2017 by MarketBeat.com Staff